AIRLINK 67.70 Increased By ▲ 2.50 (3.83%)
BOP 5.45 Decreased By ▼ -0.12 (-2.15%)
CNERGY 4.48 Decreased By ▼ -0.08 (-1.75%)
DFML 25.71 Increased By ▲ 1.19 (4.85%)
DGKC 68.75 Decreased By ▼ -1.21 (-1.73%)
FCCL 19.93 Decreased By ▼ -0.37 (-1.82%)
FFBL 30.30 Increased By ▲ 1.19 (4.09%)
FFL 9.89 Increased By ▲ 0.06 (0.61%)
GGL 10.03 Increased By ▲ 0.02 (0.2%)
HBL 114.01 Decreased By ▼ -0.24 (-0.21%)
HUBC 130.25 Increased By ▲ 1.15 (0.89%)
HUMNL 6.70 Decreased By ▼ -0.01 (-0.15%)
KEL 4.41 Decreased By ▼ -0.03 (-0.68%)
KOSM 4.80 Decreased By ▼ -0.09 (-1.84%)
MLCF 36.40 Decreased By ▼ -0.60 (-1.62%)
OGDC 132.00 Decreased By ▼ -0.30 (-0.23%)
PAEL 22.45 Decreased By ▼ -0.09 (-0.4%)
PIAA 25.65 Decreased By ▼ -0.24 (-0.93%)
PIBTL 6.64 Increased By ▲ 0.04 (0.61%)
PPL 112.72 Decreased By ▼ -0.13 (-0.12%)
PRL 29.05 Decreased By ▼ -0.36 (-1.22%)
PTC 14.87 Decreased By ▼ -0.37 (-2.43%)
SEARL 57.60 Increased By ▲ 0.57 (1%)
SNGP 66.14 Decreased By ▼ -0.31 (-0.47%)
SSGC 10.97 Decreased By ▼ -0.01 (-0.09%)
TELE 9.00 Increased By ▲ 0.20 (2.27%)
TPLP 11.60 Decreased By ▼ -0.10 (-0.85%)
TRG 68.26 Decreased By ▼ -0.36 (-0.52%)
UNITY 23.50 Increased By ▲ 0.10 (0.43%)
WTL 1.34 Decreased By ▼ -0.04 (-2.9%)
BR100 7,335 Increased By 40.4 (0.55%)
BR30 23,902 Increased By 47.4 (0.2%)
KSE100 70,541 Increased By 251.1 (0.36%)
KSE30 23,230 Increased By 59.4 (0.26%)

Widespread COVID-19 vaccinations not expected until mid-2021: WHO

  • None of the candidate vaccines in advanced clinical trials so far has demonstrated a "clear signal" of efficacy at the level of at least 50% sought by the WHO
Published September 4, 2020

The World Health Organization does not expect widespread vaccinations against COVID-19 until the middle of next year, a spokeswoman said on Friday, stressing the importance of rigourous checks on their effectiveness and safety.

None of the candidate vaccines in advanced clinical trials so far has demonstrated a "clear signal" of efficacy at the level of at least 50% sought by the WHO, spokeswoman Margaret Harris said.

Russia granted regulatory approval to a COVID-19 vaccine in August after less than two months of human testing, prompting some Western experts to question its safety and efficacy.

U.S. public health officials and Pfizer Inc said on Thursday a vaccine could be ready for distribution as soon as late October. That would be just ahead of the U.S. election on Nov. 3 in which the pandemic is likely to be a major factor among voters deciding whether President Donald Trump wins a second term.

"We are really not expecting to see widespread vaccination until the middle of next year," Harris told a U.N. briefing in Geneva.

"This phase 3 must take longer because you need to see how truly protective the vaccine is and you also need to see how safe it is," she added. This referred to the phase in vaccine research where large clinical trials among people are conducted. Harris did not refer to any specific vaccine candidate.

Comments

Comments are closed.